Loncastuximab tesirine - ADC Therapeutics

Drug Profile

Loncastuximab tesirine - ADC Therapeutics

Alternative Names: ADCT-402; Lonca-T

Latest Information Update: 02 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ADC Therapeutics
  • Class Antineoplastics; Benzodiazepines; Immunoconjugates; Monoclonal antibodies; Pyrroles
  • Mechanism of Action DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mantle-cell lymphoma; Diffuse large B cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 11 Dec 2017 Interim efficacy and safety data of a phase Ia/Ib trial in Acute lymphoblastic leukaemia released by ADC Therapeutics
  • 11 Dec 2017 Interim efficacy and safety data of a phase Ia/Ib trial in Non-Hodgkin's lymphoma released by ADC Therapeutics
  • 09 Dec 2017 Interim pharmacokinetics data from a phase I trial in Non Hodgkin lymphoma presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top